Accordingly, [177Lu]Lu-AMBA was first reported to show high therapeutic potential in several prostate cancer models having different GRPR expression levels, namely based on PC-3, LnCaP, and DU145 cells [42]. This evidence concerns the gene GRPR and prostate carcinoma.